Drug Combo Tolerated in Younger Children With Cystic Fibrosis

THURSDAY, Feb. 7, 2019 -- Lumacaftor/ivacaftor treatment is generally safe and well tolerated for children aged 2 to 5 years with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation, according to a study published online Jan. 24 in The...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news